KCNQ2 Developmental and Epileptic Encephalopathy — Research Report

sup Harry. So this one's a potassium-channel gene that, when it misfires in a newborn's brain, basically turns the volume knob on neuronal firing the wrong way during the most delicate week of a person's life. Here's the whole picture, section by section.

PMID verification key: ✅ = I confirmed the PMID/DOI live this session. 🔶 = citation pulled from a secondary source (GeneReviews, review article) — verify with just fetch-reference before curating, per the DR-verification SOP in CLAUDE.md.

1. Disease Information

What it is. KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE, historically "KCNQ2 encephalopathy" or Early Infantile Epileptic Encephalopathy type 7 / EIEE7) is the severe end of a spectrum of disorders caused by variants in KCNQ2, the gene for the Kv7.2 voltage-gated potassium channel subunit. Think of Kv7.2 as a brake pedal on neurons; when it fails, the neonatal brain seizes in the first days of life and — unlike the benign twin condition — development doesn't recover.

The KCNQ2 spectrum runs from self-limited familial neonatal epilepsy (SLFNE, formerly benign familial neonatal convulsions/seizures) at the mild end, where seizures vanish by 6–12 months and development is normal, to neonatal-onset DEE at the severe end, where the same-timed seizures come with lifelong moderate-to-profound intellectual disability. Same gene, wildly different lives, and the difference is mostly how badly the channel is broken (GeneReviews, KCNQ2-Related Disorders, 2022 update 🔶).

Key identifiers: - OMIM: 613720 (Developmental and Epileptic Encephalopathy 7, DEE7); 121200 (Seizures, benign familial neonatal, 1 / BFNS1); 602235 (the KCNQ2 gene itself) - MONDO: MONDO:0013387 (developmental and epileptic encephalopathy, 7) - Orphanet: ORPHA:439218 (KCNQ2-related developmental and epileptic encephalopathy); the SLFNE end maps to ORPHA:266 - ICD-11: 8A62 (Developmental and epileptic encephalopathies); ICD-10: G40.4 / roughly the "other generalized epilepsy and epileptic syndromes" bucket - MeSH: covered under "Spasms, Infantile" / "Epilepsy, Benign Neonatal" (D020936) and "Epileptic Syndromes" - HGNC gene: hgnc:6296 (KCNQ2)

Synonyms: KCNQ2 encephalopathy, KCNQ2-DEE, EIEE7, DEE7, neonatal-onset KCNQ2-DEE (NEO-DEE); the mild sibling is BFNC/BFNS/SLFNE.

Data provenance. Most knowledge here is aggregated disease-level (case series, functional-genetics cohorts, GeneReviews), not EHR-derived. Patient-registry data exist through the KCNQ2 Cure Alliance and the RIKEE (Rational Intervention for KCNQ2/3 Epileptic Encephalopathy) variant database, but the foundational literature is cohort- and family-based.

2. Etiology

Primary cause: genetic, monogenic. Heterozygous variants in KCNQ2 (chromosome 20q13.33). No environmental or infectious cause — this is a Mendelian channelopathy full stop.

The clean split by variant mechanism (this is the load-bearing concept for the whole disease): - Dominant-negative loss-of-function → severe neonatal DEE. A missense variant makes a poison subunit that drags down the wild-type subunits it co-assembles with, cutting M-current by >50% rather than the ~25% a simple haploinsufficiency would give. This is the classic KCNQ2-DEE mechanism (Miceli et al., 2013 🔶; Weckhuysen et al., 2012, PMID:22275249 ✅). - Simple/partial loss-of-function (haploinsufficiency) → mild SLFNE. Truncations, whole-gene deletions, ~20–30% M-current reduction. Seizures resolve, development normal. - Gain-of-function → a different, non-neonatal-seizure phenotype. GoF variants (e.g., R201C/R201H, R144, R198Q) hyperpolarize channel activation, silence neurons too much, and produce neonatal encephalopathy with non-epileptic myoclonus, later-onset DEE, autism/ID with language impairment — often WITHOUT neonatal seizures. The absence of neonatal seizures is the single best clinical tell for GoF (Mulkey et al., 2017 🔶; Miceli et al., 2015 🔶; the R144 GoF paper, eBioMedicine 2022 🔶).

Risk factors. Essentially none beyond carrying the variant. Because severe KCNQ2-DEE variants are overwhelmingly de novo, there's no meaningful "risk factor" story — no maternal exposure, no prematurity link, no infection. Family history matters only for the milder inherited SLFNE end.

Protective factors. None genetically established. The most interesting "protective" signal is therapeutic timing, not innate: earlier initiation of sodium-channel-blocker therapy may blunt phenotype severity (see §12).

Gene–environment interactions. No established GxE for KCNQ2-DEE. This is about as close to "pure genotype" as neurodevelopmental disease gets.

3. Phenotypes

The core clinical picture, with suggested HPO terms and frequencies drawn from Weckhuysen 2012 (PMID:22275249 ✅) and GeneReviews 🔶:

Severity/progression pattern (this is the important bit): the seizures are episodic and often remit by age 9 months–4 years, but the encephalopathy is static-to-slowly-improving and lifelong. That decoupling is exactly why the field renamed it from "epileptic encephalopathy" to "developmental AND epileptic encephalopathy" — there's a developmental component that isn't just a consequence of the seizures (the debate is nicely framed in "KCNQ2-DEE: developmental or epileptic encephalopathy?" Epilepsia Open 🔶, PMC7951099).

Quality-of-life impact: severe. Most individuals at the DEE end are nonverbal, non-ambulatory or limited, require full care, and have feeding, communication, and mobility support needs across the lifespan. A 2025 qualitative study of lived experience (Epilepsy & Behavior 🔶) documents high caregiver burden and the developmental-regression fear tied to medication weaning.

4. Genetic / Molecular Information

Causal gene: KCNQ2 (potassium voltage-gated channel subfamily Q member 2), 20q13.33, HGNC:6296, OMIM 602235. Encodes Kv7.2, a 6-transmembrane (S1–S6) voltage-gated K⁺ channel subunit: S1–S4 voltage sensor, S5–S6 pore, and a long intracellular C-terminus with four calmodulin-binding/subunit-assembly helices (A–D).

Discovery lineage (for provenance): - Singh et al., 1998, Nat Genet 18:25–29 — KCNQ2 mutated in BFNC 🔶 (commonly cited PMID:9425895) - Biervert et al., 1998, Science 279:403–406 — potassium channel mutation in neonatal epilepsy 🔶 (PMID:9430337) - Charlier et al., 1998, Nat Genet — KCNQ3 as the second BFNC gene 🔶 (PMID:9425900) - Weckhuysen et al., 2012, Ann Neurol 71:15–25 — carved out the severe encephalopathy phenotype (PMID:22275249 ✅)

Variant classes (ACMG/AMP-classified in ClinVar): - Missense dominates the DEE end (dominant-negative). Recurrent hotspot residues cluster in four high-risk zones: the S4 voltage sensor (e.g., R198, R201, R213, R214), the pore (e.g., around residue 281), the proximal C-terminus, and the C-terminal B-helix (Millichap et al., 2016, Neurol Genet 🔶). Recurrent DEE alleles include R201C/R201H, R213W/R213Q, A294V, and the pore variant G281 series. - Truncating / frameshift / nonsense / whole-gene deletions → generally the milder SLFNE (haploinsufficiency), though not exclusively. - In-frame indels can behave dominant-negatively. - Deletion/duplication (CNV) accounts for <10% of pathogenic findings; sequence analysis catches >90% 🔶.

Allele frequency: DEE-causing variants are absent from population databases (gnomAD) — they're de novo and highly penetrant, so they don't persist in the general population. This absence is itself an ACMG PM2 supporting criterion.

Origin: germline, de novo for the vast majority of DEE cases; germline/gonadal mosaicism in an unaffected parent has been reported and is the reason recurrence risk is quoted as low-but-not-zero (~1–2%+).

Functional consequences: loss-of-function (haploinsufficiency), dominant-negative loss-of-function (the DEE workhorse), and gain-of-function (distinct phenotype). A 2025 paper adds a genuinely novel wrinkle — some DEE variants act by introducing abnormal current inactivation rather than pure current reduction, a fourth biophysical mechanism ("Potassium current inactivation as a novel pathomechanism," PMC12169393 🔶).

Modifier genes / epigenetics / chromosomal abnormalities: no established Mendelian modifier genes, no disease-specific methylation signature (episignature) validated for KCNQ2-DEE as of this writing, and no recurrent large chromosomal rearrangement beyond the 20q13.33 CNVs noted above.

5. Environmental Information

Short section, and honestly a relief to write: no environmental, lifestyle, or infectious contribution is established. KCNQ2-DEE is a de novo monogenic channelopathy. Toxins, radiation, occupational exposure, diet, infection — none are causal or triggering in any documented way. The only "environmental" lever anyone can pull is treatment choice and timing (§12).

6. Mechanism / Pathophysiology

Here's the causal chain, from broken protein to seizing baby. This is the meat for the pathophysiology nodes.

Upstream — the channel and the M-current. Kv7.2 (KCNQ2) co-assembles with Kv7.3 (KCNQ3) into heterotetramers that carry the M-current (I_M / I_Kv7) — a slowly activating, non-inactivating, sub-threshold K⁺ current. Because it's active near resting potential and doesn't inactivate, the M-current is a persistent leak that: 1. sets and stabilizes the resting membrane potential, 2. produces spike-frequency adaptation (it clamps down repetitive firing), and 3. dampens overall neuronal excitability.

Crucially, these channels are concentrated at the axon initial segment (AIS) and nodes of Ranvier, anchored there via ankyrin-G-binding motifs — the exact spots where action potentials are born and propagated (Devaux et al., 2004, "KCNQ2 is a nodal K⁺ channel," J Neurosci, PMID:14762142 ✅; Pan et al., PNAS 🔶). So Kv7.2 isn't a diffuse background brake — it's a brake bolted right onto the ignition switch.

GO / CL / UBERON anchors: - Biological processes: regulation of membrane potential (GO:0042391), potassium ion transmembrane transport (GO:0071805), regulation of neuronal action potential (GO:0098908), negative regulation of neuron differentiation/excitability, spike-frequency adaptation. - Molecular function: voltage-gated potassium channel activity (GO:0005249). - Cellular components: axon initial segment (GO:0043194), node of Ranvier (GO:0033268), plasma membrane (GO:0005886). - Cell types (CL): glutamatergic neuron (CL:0000679), pyramidal neuron (CL:0000598), CNS interneuron / GABAergic interneuron (CL:0000617) — GoF pathology is thought to preferentially silence excitatory neurons or disrupt interneuron circuits. - Anatomy (UBERON): cerebral cortex (UBERON:0000956), hippocampus (UBERON:0002421), brain (UBERON:0000955); the basal ganglia show transient neonatal MRI changes.

Midstream — what the variant does. A dominant-negative missense subunit incorporates into the tetramer and poisons it, so M-current drops >50%. Less brake → the AIS/nodes fire too readily → neuronal hyperexcitability and hypersynchrony → neonatal seizures.

The gain-of-function paradox. GoF variants do the opposite biophysically — too much K⁺ current, neurons over-silenced — yet still cause encephalopathy, likely by disrupting the excitation/inhibition balance at the circuit level (over-silencing excitatory cells, or knocking out interneuron function). This is why the two mechanisms need opposite drugs (Kv7 opener helps LoF, harms GoF).

Downstream — the developmental arm. Kv7 channels aren't just firing regulators; they shape neuronal maturation. A 2025 iPSC study shows LoF variants cause early hyperexcitability followed by maladaptive network remodeling during development (bioRxiv 2025.07.22 🔶), which is the mechanistic candidate for why the developmental deficit outlasts the seizures. That's the crux of the "developmental AND epileptic" reframing.

Conformance note for the KB: the core of this maps cleanly onto the cardiac_ion_channel_repolarization module's sibling logic and, more directly, the epilepsy_excitation_inhibition_imbalance module — KCNQ2-DEE is essentially a textbook conformer of epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance (ion-channel dysfunction → E/I imbalance → hyperexcitability/hypersynchrony → seizures → epileptogenesis). Worth flagging when this entry gets curated.

Molecular profiling: most mechanistic data are electrophysiological (patch-clamp of heterologously expressed channels in Xenopus oocytes / CHO / HEK cells — IN_VITRO evidence) and, increasingly, patient-derived iPSC neurons (also IN_VITRO). No robust transcriptomic/proteomic/metabolomic disease signature from patient tissue exists — you can't biopsy a neonatal brain.

7. Anatomical Structures Affected

• Organ level: brain (UBERON:0000955) — primarily. This is a CNS-restricted disorder; no systemic organ involvement. Body system: nervous system (central).
• Regions: cerebral cortex (UBERON:0000956), hippocampus (UBERON:0002421); basal ganglia (UBERON:0002420) show transient neonatal T1/T2 or diffusion changes on MRI; later, nonspecific white-matter changes and volume loss.
• Tissue/cell level: nervous tissue; neurons — pyramidal/glutamatergic (CL:0000598/CL:0000679) and GABAergic interneurons (CL:0000617). The functional lesion sits at the axon initial segment and nodes of Ranvier.
• Subcellular: plasma membrane at the AIS (GO:0043194) and node of Ranvier (GO:0033268).
• Lateralization: bilateral / diffuse encephalopathy; individual seizures are often focal-onset (can shift sides — multifocal) but the disease burden is bilateral.

8. Temporal Development

• Onset: neonatal, median day 1 of life, essentially always within the first week (Weckhuysen 2012, PMID:22275249 ✅). Onset pattern is acute (dramatic multiple-daily seizures from the start).
• Course: seizures are frequent and drug-resistant at onset, then typically improve and remit between ~9 months and 3–4 years. The encephalopathy is static-to-lifelong — developmental impairment persists after seizure remission.
• Stages: (1) neonatal explosive-seizure phase with burst-suppression/multifocal EEG; (2) seizure-attenuation phase in infancy/early childhood; (3) chronic static encephalopathy with variable later-life epilepsy relapse.
• Progression rate: the neurodevelopmental deficit is non-progressive (static encephalopathy) in most — not a neurodegeneration. Severity is set early.
• Critical window: the neonatal period is both the window of maximal vulnerability and the proposed window of therapeutic opportunity — the "treat early, treat right" hypothesis (Pisano et al., 2015, Epilepsia, "Early and effective treatment of KCNQ2 encephalopathy" 🔶).
• Duration: chronic, lifelong disability; seizures self-limit but the disorder does not.

9. Inheritance and Population

Inheritance: autosomal dominant. - KCNQ2-DEE (severe): overwhelmingly de novo; penetrance is complete. Reproduction is rare, so vertical transmission is uncommon. - SLFNE (mild): usually inherited from an affected parent; penetrance incomplete (~77–85%) 🔶. - Germline/gonadal mosaicism occurs and drives the low-but-nonzero sibling recurrence risk. - Anticipation: not a repeat-expansion disorder — no genetic anticipation. - Founder effects / consanguinity: not relevant (dominant, de novo). - Carrier frequency: N/A for the de novo dominant DEE end.

Epidemiology: - KCNQ2 is one of the most common genetic causes of neonatal-onset epileptic encephalopathy — it was found in ~10% of 80 unexplained neonatal/early-infantile seizure-plus-delay cases in the founding cohort (Weckhuysen 2012, PMID:22275249 ✅). - Incidence of KCNQ2-related neonatal epilepsy estimated at roughly ~5.9 per 100,000 live births (<6 months) in a Scottish population cohort (Symonds et al., 2019, Brain 🔶 — verify PMID before curation). - Documented individuals: on the order of a few hundred reported NEO-DEE cases plus ~200 SLFNE families 🔶; it's a rare disease but not vanishingly so among neonatal epilepsies. - Sex ratio: roughly 1:1 — no sex bias (X-autosomal; gene is autosomal). - Geography/ethnicity: no population clustering; reported worldwide across ancestries.

Prevalence class for the KB: qualitatively RARE; incidence ~5.9/100,000 live births → rate_per_100000 ≈ 5.9 (ANNUAL_INCIDENCE / BIRTH_PREVALENCE framing), Orphanet band roughly BAND_1_9_PER_100000.

10. Diagnostics

Genetic testing is the definitive diagnostic. - Approach: clinical suspicion (neonatal tonic seizures + burst-suppression/multifocal EEG + encephalopathy) → next-generation sequencing. Options: multigene neonatal-epilepsy/DEE panel (fastest yield in the NICU), exome/genome sequencing (rapid trio WES/WGS increasingly first-line for neonatal seizures), or single-gene KCNQ2 sequencing. Sequence analysis detects >90%; add deletion/duplication (CMA/MLPA) for the <10% CNV cases 🔶. - Interpretation: classify per ACMG/AMP; DEE variants are typically de novo (PS2), absent from gnomAD (PM2), at known hotspots/recurrent (PS1/PM1/PM5), with functional data (PS3) from patch-clamp — a strong combination that often reaches pathogenic.

Electrophysiology (central to the phenotype): - EEG: at DEE onset, burst-suppression pattern or multifocal epileptiform activity; SLFNE shows normal-to-focal discharges that normalize. Serial EEG is used for surveillance. - Ictal semiology: focal-onset tonic seizures with autonomic/apneic features.

Neuroimaging: - Brain MRI: often normal early, or transient basal ganglia and thalamic hyperintensity/restricted diffusion in the neonatal period; later nonspecific white-matter change or volume loss. MRI helps exclude structural/hypoxic-ischemic mimics rather than confirm KCNQ2-DEE.

Laboratory / biomarkers: no specific blood, CSF, or metabolic biomarker. Routine metabolic workup (glucose, electrolytes, ammonia, lactate, CSF, acylcarnitines, etc.) is done to exclude treatable metabolic/infectious causes of neonatal seizures — it's a rule-out, not a rule-in. No LOINC-coded diagnostic analyte for the disease itself.

Differential diagnosis: other genetic neonatal DEEs — SCN2A, SCN8A, STXBP1, KCNQ3, ARX, CDKL5, KCNT1, pyridoxine-dependent epilepsy (ALDH7A1) and other treatable metabolic epilepsies, and hypoxic-ischemic encephalopathy. KCNQ3 neonatal epilepsy is clinically near-indistinguishable at the mild end.

Screening: KCNQ2 is not on standard biochemical newborn screening (it's not a metabolic disease). Cascade/family testing applies mainly to the inherited SLFNE end. Prenatal/PGT is technically possible when a familial variant is known but is rarely relevant for the de novo DEE cases.

11. Outcome / Prognosis

• Survival: most individuals survive into adulthood; there is an elevated risk of SUDEP (sudden unexpected death in epilepsy) and mortality from severe-disability complications, but KCNQ2-DEE is not typically early-lethal. Life expectancy is reduced by comorbidity burden, not by a defined disease-specific lethal course.
• Seizure prognosis: relatively good — seizures usually remit in infancy/early childhood (9 mo–4 yr), though a subset relapse later.
• Developmental prognosis: poor and the dominant driver of outcome — moderate-to-profound intellectual disability, frequently nonverbal, motor impairment, feeding/communication needs. The encephalopathy persists regardless of seizure control.
• Prognostic factors: the strongest predictor is variant functional severity — degree of in-vitro M-current reduction correlates with long-term neurodevelopmental outcome (PMC7415140, "Heteromeric Kv7.2 current changes… correlated with long-term neurodevelopmental outcomes" 🔶). Dominant-negative > simple LoF in severity. Earlier effective therapy (sodium-channel blockers) may improve outcome (Pisano 2015 🔶).
• QoL measures: no KCNQ2-specific validated instrument; generic pediatric DEE/QI-Disability and caregiver-burden tools are used.

12. Treatment

This is where KCNQ2-DEE gets genuinely interesting as a precision-medicine story, because the right drug depends on the biophysics of the variant.

First-line: sodium channel blockers (the standout for loss-of-function). - Carbamazepine, oxcarbazepine, phenytoin, lacosamide. Multiple series show these outperform broad-spectrum ASMs in KCNQ2-DEE. Reported seizure-freedom rates: carbamazepine ~40% within 2 weeks, phenytoin ~33–42%, oxcarbazepine ~53% in one comparison 🔶. - Why it works: Kv7 potassium channels and Naᵥ sodium channels co-localize at the AIS; blocking the sodium channels compensates for the missing potassium brake (down-regulating the excitatory current that the failed K⁺ channel can no longer restrain) 🔶. - MAXO/CHEBI anchors: Pharmacotherapy (NCIT:C15986); agents — carbamazepine (CHEBI:3387), oxcarbazepine (CHEBI:7824), phenytoin (CHEBI:8107), lacosamide (CHEBI:87517). therapeutic_modality: SMALL_MOLECULE.

Targeted / mechanism-based: Kv7 channel openers (retigabine/ezogabine). - Ezogabine (retigabine, XEN496) directly opens Kv7.2/7.3 channels — it's the mechanistically "perfect" drug for loss-of-function variants. A retrospective series (Knight et al., 2023, Epilepsia, DOI:10.1111/epi.17627 ✅) of 8 KCNQ2-DEE patients found ≥50% seizure reduction in the 5 with daily seizures, developmental improvement in all 8, and — tellingly — weaning caused seizure increase, irritability, poor sleep, and developmental regression. - BUT: retigabine was withdrawn from market in 2017 for retinal pigmentation and blue skin/mucosal discoloration with chronic use. A reformulated pediatric version (XEN496/ezogabine) ran a Phase 3 RCT (NCT04639310, EPIK), which was terminated in May 2023 for a sponsor business decision, not safety ✅. So the ideal targeted drug currently has no approved pediatric product — a real unmet-need gap. - Genotype caveat: for gain-of-function variants a Kv7 opener is the wrong direction and can worsen the phenotype; those patients theoretically need Kv7 blockers/negative modulators 🔶. This LoF-vs-GoF drug divergence is the reason functional variant classification matters clinically, not just academically. - MAXO anchor for ezogabine: Pharmacotherapy (NCIT:C15986), agent ezogabine/retigabine (CHEBI:78754), therapeutic_modality: SMALL_MOLECULE, with a target_mechanisms link back to the Kv7/M-current node.

Supportive / adjunctive: phenobarbital (common neonatal first agent, though less specific), levetiracetam, topiramate, benzodiazepines; ketogenic diet (MAXO:0000088, dietary intervention) in refractory cases; standard DEE supportive care — PT/OT/speech, feeding support, developmental services (MAXO:0000950 supportive care; NCIT:C15315 rehabilitation).

Experimental horizon: antisense oligonucleotide and other genetic approaches are in preclinical development (allele-selective knockdown for dominant-negative alleles is a conceptually clean strategy; iPSC/mouse work is underway), and small-molecule Kv7 modulators beyond ezogabine are being pursued. Nothing approved yet.

Pharmacogenomics: the "pharmacogenomics" here IS the disease genotype — LoF vs GoF classification of the KCNQ2 variant is the single most important treatment-guiding factor. This is genotype-guided therapy in its purest form.

13. Prevention

• Primary prevention: not possible for de novo variants — you can't prevent a spontaneous germline mutation. No vaccine, no modifiable risk factor.
• Secondary prevention / early detection: the meaningful lever is rapid genetic diagnosis in the NICU (rapid trio exome/genome for neonatal seizures) so that variant-appropriate therapy (sodium channel blockers / Kv7 openers) starts early — the "treat early and right" strategy that may improve developmental outcome (Pisano 2015 🔶). That's secondary prevention of severity, not of the disease.
• Tertiary prevention: seizure control, SUDEP-risk management, developmental/rehabilitative support to prevent complications.
• Genetic counseling: essential. For de novo DEE, recurrence risk is low (~1–2%, driven by possible parental gonadal mosaicism); for inherited SLFNE, standard 50% AD transmission with incomplete penetrance. PGT/prenatal testing available when a familial variant is known (MAXO:0000079 genetic counseling; NSGC/ACMG frameworks).
• Immunization / public-health / environmental interventions: not applicable.

14. Other Species / Natural Disease

• Taxonomy / orthologs: KCNQ2 is deeply conserved. Mouse Kcnq2 (NCBITaxon:10090, Mus musculus), rat Kcnq2 (NCBITaxon:10116), zebrafish kcnq2 (NCBITaxon:7955). Human ortholog KCNQ2 (NCBI Gene 3785).
• Natural disease in animals: no well-documented spontaneous naturally-occurring KCNQ2 neonatal epilepsy in companion animals or wildlife is catalogued in OMIA the way, say, some canine epilepsies are. The disease knowledge is essentially all human + engineered models.
• Comparative biology: the M-current and Kv7.2/7.3 AIS localization are conserved across mammals, which is why rodent models recapitulate the human electrophysiology well — the brake pedal is built the same way across species.
• Zoonosis / transmission: N/A — genetic, non-transmissible.

15. Model Organisms

Rodent models are strong here and are the backbone of mechanistic and preclinical-therapeutic work. Evidence source = MODEL_ORGANISM.

• Conditional dominant-negative Kcnq2 transgenic mice (Peters et al., 2005): suppress M-current → spontaneous seizures, hippocampal memory impairment, behavioral hyperactivity — an early demonstration that M-current loss alone produces the seizure+cognitive phenotype 🔶.
• Knock-in point-mutant mice reproducing human alleles:
• Kcnq2 Thr274Met/+ knock-in — viable, spontaneous generalized seizures from ~P20–P30 with cognitive impairment (Milh/Marini group, 2020, Epilepsia, PMID:32239694 ✅). A faithful DEE-like model.
• Kcnq2 A306T and Kcnq3 G311V knock-ins — survive into adulthood with spontaneous lifelong seizures 🔶.
• Calmodulin-binding-domain variant mice — spontaneous seizure + memory loss (PMC8713762 🔶).
• cKcnq2 M547V conditional mice — early mortality, spontaneous seizures, enhanced seizure susceptibility, memory deficits, repetitive behaviors 🔶.
• Tg Kcnq2 G279S mice — partial seizures ± secondary generalization 🔶.
• Conventional Kcnq2 knockout: homozygous null is neonatal-lethal (pulmonary/dysfunctional), consistent with the channel's essential role — hence the field's reliance on heterozygous and conditional models. Good review: Brun et al., 2022, "Mouse models of Kcnq2 dysfunction," Epilepsia 🔶.
• iPSC-derived human neuron models (IN_VITRO): patient-derived and CRISPR-engineered iPSC neurons now recapitulate variant-specific hyperexcitability and drug responses, including the 2025 machine-learning-phenotyping and maladaptive-remodeling studies (bioRxiv 2025 🔶) — increasingly used for variant functional classification and drug screening.
• Heterologous expression (IN_VITRO): Xenopus oocytes and CHO/HEK cells for patch-clamp are the standard for scoring a new variant as LoF/DN/GoF — the assay that feeds the ACMG PS3 criterion and the treatment decision.

Model strengths: rodent knock-ins reproduce spontaneous seizures, cognitive deficits, and the electrophysiology, and respond to Kv7 openers — good for preclinical drug testing. Limitations: rodents don't fully model the human developmental/cognitive trajectory or the neonatal timing precisely; homozygous KO lethality limits complete-loss modeling; and human-specific circuit biology is only approximated (a candidate HUMAN_MODEL_MISMATCH discussion note for the KB where mouse timing/severity diverges from human).

Resources: MGI (mouse), RGD (rat), ZFIN (zebrafish), IMPC/KOMP for Kcnq2 alleles; the RIKEE database (rikee.org) as the human variant-function registry.

Curation notes for the dismech entry

A few things worth carrying into the YAML when this gets built: - Module conformance: strong candidate conformer for epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance (ion-channel dysfunction → E/I imbalance → hyperexcitability/hypersynchrony → seizures). The Kv7-opener treatment pattern fits the target_mechanisms drug convention. - The LoF/DN/GoF split should be modeled explicitly (probably as subtypes or mechanistic_hypotheses with hypothesis_group_id), since it drives both phenotype and opposite-direction treatment. - Evidence-source discipline: electrophysiology and iPSC data = IN_VITRO; mouse knock-ins = MODEL_ORGANISM; keep the neonatal-seizure/EEG/outcome claims on HUMAN_CLINICAL sources (Weckhuysen 2012, Knight 2023). - Verify before committing: PMIDs marked �remaining (Singh 9425895, Biervert 9430337, Charlier 9425900, Miceli 2013/2015, Millichap 2016 27353566, Mulkey 2017, Symonds 2019) came from GeneReviews/reviews — run just fetch-reference and confirm snippets are exact substrings per the anti-hallucination SOP. The ones I confirmed live this session are Weckhuysen (22275249), Devaux nodal K⁺ (14762142), the Thr274Met mouse (32239694), and the Knight ezogabine paper (DOI 10.1111/epi.17627).

Sources: - GeneReviews: KCNQ2-Related Disorders (NBK32534) - OMIM #613720 — DEE7 · OMIM *602235 — KCNQ2 · OMIM #121200 — BFNS1 - Orphanet: KCNQ2-related DEE (439218) · NORD: KCNQ2-DEE - Weckhuysen et al. 2012, Ann Neurol (PMID:22275249) - Devaux et al. 2004, KCNQ2 is a nodal K⁺ channel (PMID:14762142) - Knight et al. 2023, Ezogabine in KCNQ2-DEE, Epilepsia · NCT04639310 (XEN496/EPIK) - Knock-in Kcnq2 Thr274Met mouse (PMID:32239694) · Brun et al. 2022, Mouse models of Kcnq2 dysfunction - KCNQ2-DEE: developmental or epileptic encephalopathy? (PMC7951099) · Heteromeric Kv7.2 current & outcomes (PMC7415140) - Potassium current inactivation as novel pathomechanism (PMC12169393) · R144 gain-of-function, eBioMedicine 2022 - KCNQ2 Cure Alliance — What is KCNQ2 Epilepsy

That's the whole animal, nose to tail. The one-line version if you're skimming: it's a de novo dominant potassium-channel brake failure that seizes newborns in week one, the seizures fade but the brain stays hurt, and — unusually — knowing whether the channel is too weak or too strong literally flips which drug you reach for. Want me to go ahead and scaffold the actual kb/disorders/KCNQ2_Developmental_and_Epileptic_Encephalopathy.yaml entry from this, or open a curation issue for it?